CHF-6366

N/A

Report date: 2024/04/16 20:00:32
NME

Base Information

Drug NameCHF-6366
Drug Alias NameCHF-6366
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-2 adrenergic receptor agonistsMuscarinic acetylcholine receptor M3 antagonists
TargetsBeta-2 adrenergic receptorMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChiesi Farmaceutici SPA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChiesi Farmaceutici SPA
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A
Related LinksN/A